RxDoctor Payments Data

Morgan McClintic, OD

Optometrist · Waitsfield, VTNPI 1700447026

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 22 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by AbbVie at 45.7% of the total. Reporting peaked in 2020 at $227 and has fallen 96.0% since, to $9 in 2025.

$509in general payments, 2019–2025

Across 22 payments — averaging $23.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$233
  • Alcon$127
  • Novartis$41
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$23
  • Johnson & Johnson Vision Care, Inc.$20
  • Coopervision Inc.$17
  • plus $49 from 4 others

What the payments were for

  • Food & beverage$509100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$509 in reported general payments places this provider in the 75th percentile of 80 optometrist providers in Vermont.

See all optometrist providers in Vermont

Medicare billing

Part B allowed, 2024
$27,628
Medicare patients
183
Services billed
328

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MieboPerfluorohexyloctane/Pf21$15,391
Latanoprost49$677
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha11$162

Paid to pharmacies, not to this prescriber.

Other optometrist in Waitsfield

See the full list for Vermont

Where these figures come from

Is this you, or does something look wrong? →